Imperial College London
Alternate

DrJonathanBaker

Faculty of Medicine, National Heart & Lung Institute

Honorary Senior Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 7790jonathan.baker

 
 
//

Location

 

223Guy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Baker:2018:10.1165/rcmb.2018-0187ED,
author = {Baker, JR},
doi = {10.1165/rcmb.2018-0187ED},
journal = {American Journal of Respiratory Cell and Molecular Biology},
pages = {412--414},
title = {Sirtuin-1: a new potential therapeutic target for rhinosinusitis? Who 'nose'?},
url = {http://dx.doi.org/10.1165/rcmb.2018-0187ED},
volume = {59},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Chronic rhinosinusitis is one of the most common upper respiratory tract diseases. In the  USA  chronic  rhinosinusitis  has  a  high  prevalence,  with  around  12%  of  the population having the disease, and therefore as a consequence the disease has a high health cost burden (1). Chronic rhinosinusitis is classified as an inflammatory nasal disease in which the nasal cavities become inflamed and swollen. The disease can be divided into two distinct disease phenotypes: Chronic rhinosinusitis without nasal polyps (CRSsNP) and Chronic rhinosinusitis with nasal polyps(CRSwNP) (2). One  of  the  major  clinical  differences  between  the  two  subsets  of  disease  is  that CRSwNP  patients  form  nasal  polyps  within  their  nasal  cavities,  with  these  being described  as  inflammatory  lesions  of  sinonasal  tissue  which  further  narrow  this space  (3).  This  leads  to  symptoms  of  nasal  congestion,  rhinorrhoea  and  facial pressure or pain that is of duration of 12 weeks or longer (3). CRSwNP is believed to be a disease of eosinophilia, with an impaired sinonasal epithelial barrier that causes hypersensitivity  to  inhaled  pathogens  and  particulates,  as  well  as  increased permeability, exacerbating the recruitment of inflammatory cells in response to the stimulus.
AU  - Baker,JR
DO  - 10.1165/rcmb.2018-0187ED
EP  - 414
PY  - 2018///
SN  - 1044-1549
SP  - 412
TI  - Sirtuin-1: a new potential therapeutic target for rhinosinusitis? Who 'nose'?
T2  - American Journal of Respiratory Cell and Molecular Biology
UR  - http://dx.doi.org/10.1165/rcmb.2018-0187ED
UR  - https://www.ncbi.nlm.nih.gov/pubmed/29995434
UR  - https://www.atsjournals.org/doi/abs/10.1165/rcmb.2018-0187ED
UR  - http://hdl.handle.net/10044/1/62302
VL  - 59
ER  -
Download